Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.35 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022359 | 0.85 | NOS3 (0.38) | ROCK2ROCK1CYP1A2TSHRHRH4 | |
| SCHEMBL13460691 | 0.82 | USP2 (0.45) | CYP1A2TSHRCHKA | |
| SCHEMBL9117477 | 0.82 | — | — | |
| SCHEMBL17912452 | 0.73 | CHRNA7 (0.39) | CYP1A2TSHR | |
| SCHEMBL4073814 | 0.72 | INMT (0.43) | CYP1A2TSHRCHKA | |
| SCHEMBL12983671 | 0.72 | INMT (0.48) | CYP1A2TSHRCHKA | |
| SCHEMBL8065689 | 0.72 | — | — | |
| SCHEMBL8046555 | 0.72 | — | — | |
| SCHEMBL51453 | 0.72 | INMT (0.48) | CYP1A2TSHRCHKA | |
| SCHEMBL8056671 | 0.72 | INMT (0.39) | CYP1A2TSHRCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084847-B2 | Polyamide compound and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084847-B2 | Polyamide compound and use thereof | OPRK1, OPRM1, OPRD1 | ROCK2 1770/4885ROCK1 1516/4885CYP1A2 241/4885 |
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | ROCK2 3414/4885ROCK1 3433/4885CYP1A2 1973/4885 |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | ROCK2 739/4885ROCK1 880/4885CYP1A2 1621/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | ROCK2 3449/4885ROCK1 3657/4885CYP1A2 21/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | ROCK2 739/4885ROCK1 880/4885CYP1A2 1621/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | ROCK2 3414/4885ROCK1 3433/4885CYP1A2 1973/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | ROCK2 3343/4885ROCK1 3520/4885CYP1A2 27/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | ROCK2 1702/4885ROCK1 1235/4885CYP1A2 96/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | ROCK2 1129/4885ROCK1 701/4885CYP1A2 98/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | ROCK2 2912/4885ROCK1 3274/4885CYP1A2 11/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | ROCK2 3414/4885ROCK1 3433/4885CYP1A2 1973/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | ROCK2 3414/4885ROCK1 3433/4885CYP1A2 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.